Baxter stops making multidose heparin

Docs needing blood-thinning drugs may be in a fix. Allergic reactions prompted Baxter to stop making multiple-dose vials of heparin, and the FDA told physicians to stop using them except when absolutely necessary--and then, very carefully. Baxter makes 35 million vials of heparin annually, about half the U.S. supply, making officials worry about shortages.

You'll recall that late last month, Baxter recalled nine lots of the injectable heparin after dialysis patients had allergic reactions to it. Now, the FDA says it has received 350 reports of side effects including vomiting, nausea, and difficulty breathing. Four people died while taking the drug, but it's not clear the drug was to blame. The FDA is inspecting Baxter's manufacturing facilities in search of the problem.

- check out Baxter's release
- read the report
- get more details from the Chicago Tribune

Related Articles:
Baxter recalls heparin on adverse events. Report
Quaid sues Baxter over Heparin. Report
Heparin overdose at Cedars-Sinai. Report
Third baby dies at IN hospital. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.